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Abstract
Introduction: Genome wide association studies, replicated by numerous well powered validation studies, have
revealed a large number of loci likely to play a role in susceptibility to many multifactorial diseases. It is now well
established that some of these loci are shared between diseases with similar aetiology. For example, a number of
autoimmune diseases have been associated with variants in the PTPN22, TNFAIP3 and CTLA4 genes. Here we have
attempted to define overlapping genetic variants between rheumatoid arthritis (RA), type 1 diabetes (T1D) and
coeliac disease (CeD).
Methods: We selected eight SNPs previously identified as being associated with CeD and six T1D-associated SNPs
for validation in a sample of 3,962 RA patients and 3,531 controls. Genotyping was performed using the Sequenom
MassArray platform and comparison of genotype and allele frequencies between cases and controls was
undertaken. A trend test P-value < 0.004 was regarded as significant.
Results: We found statistically significant evidence for association of the TAGAP locus with RA (P = 5.0 × 10
-4). A
marker at one other locus, C1QTNF6, previously associated with T1D, showed nominal association with RA in the
current study but did not remain statistically significant at the corrected threshold.
Conclusions: In exploring the overlap between T1D, CeD and RA, there is strong evidence that variation within
the TAGAP gene is associated with all three autoimmune diseases. Interestingly a number of loci appear to be
specific to one of the three diseases currently studied suggesting that they may play a role in determining the
particular autoimmune phenotype at presentation.
Introduction
Rheumatoid arthritis (RA) is an auto-immune, inflam-
matory joint condition, affecting 0.8% of the UK popula-
tion [1]. It has long been established that the major
genetic predisposition to this disease is contributed by
variants of the class II HLA gene, HLA DRB1. Both type
1 diabetes (T1D) and coeliac disease (CeD) are also
auto-immune, inflammatory diseases for which the
major genetic contribution arises from the major histo-
compatibility complex and which are also characterised
by autoantibody formation [2].
Recent genome wide association and subsequent replica-
tion studies in these three diseases have revealed a large
number of well validated, non-HLA genetic risk loci pro-
viding an opportunity to explore the possibility of overlap-
ping susceptibility between them [3]. Testing confirmed
T1D susceptibility loci in CeD samples has already
resulted in the identification of novel CeD loci [2].
* Correspondence: steve.eyre@manchester.ac.uk
1Arthritis Research UK-Epidemiology Unit, Stopford Building, Oxford Road,
The University of Manchester, Manchester M13 9PT, UK
Full list of author information is available at the end of the article
Eyre et al. Arthritis Research & Therapy 2010, 12:R175
http://arthritis-research.com/content/12/5/R175
© 2010 Eyre et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.A previous study exploring the overlap of CeD and RA
susceptibility loci identified association to six regions [4].
We have recently reported our findings of the testing of
putative T1D susceptibility loci in RA, which identified
AFF3 as a novel RA susceptibility locus [5]. However,
exploring the overlap between the three diseases in more
detail may provide a further opportunity to elucidate the
genetic similarities, and differences, between these com-
mon autoimmune diseases.
We, therefore, tested 14 validated susceptibility loci
from CeD and T1D in a large, well powered cohort of
British Caucasian patients with RA and independent
controls to explore the overlap between loci identified
in all three conditions.
Materials and methods
Samples
Clinical characteristics of the RA case-control cohort
tested have been described previously [6]. RA cases
satisfied American College of Rheumatology (ACR) clas-
sification criteria for RA modified for genetic studies, all
provided informed consent and were collected with ethi-
cal committee approval (North-West Multi-Centre
Research Ethics Committee (MREC 99/8/84) and the
University of Manchester Committee on the Ethics of
Research on Human Beings) [7,8]. Their clinical charac-
teristics are shown in Table S1 in Additional file 1.
SNP selection
SNP markers with evidence for association with CeD sus-
ceptibility (P <1×1 0
-5) in reference [2] were selected for
genotyping in a cohort of RA and control samples.
Where more than one SNP was associated at a particular
locus with CeD, the most associated variant was selected
for genotyping in the RA case-control cohort.
SNP markers with evidence for association in T1D in
the same reference, but not genotyped as part of our
previous work, were also selected for genotyping in the
current cohort of RA cases and controls.
Genotyping
SNP markers were genotyped using the iPlex chemistry
on the Sequenom platform according to the manufac-
turer’s instructions (Sequenom, San Diego, California,
USA) [9]. Duplicate samples and negative controls were
included on the plates to ensure genotyping accuracy.
Additional quality control measures were introduced
such that only SNP markers and samples exceeding a
90% genotyping success threshold were included in any
subsequent analysis.
Analysis
The power to detect association in the current cohort
assuming the same odds ratio (OR) as was reported in
the CeD disease study was calculated using Quanto [10].
Departure from Hardy-Weinberg equilibrium was tested
for all SNP markers. Genotype frequencies were com-
pared between RA cases and controls using the trend
test implemented in STATA (StataCorp LP, Texas,
USA). Conditional logistic regression was used to assess
whether effects were independent where two SNPs had
been tested at the same locus.
Results
SNP selection
Eight CeD SNPs were selected for genotyping as they
had not previously been examined for association with
RA (Table 1). We have previously reported our results
for most but not all of the T1D loci tested in a recent
study exploring the genetic overlap between CeD and
T 1 D[ 5 ] .F o rc o m p l e t e n e s s ,s i xT 1 Da s s o c i a t e dS N P s
not previously investigated for association with RA in
the current data set were, therefore, also tested (Table
2).
Genotyping
Genotyping was undertaken in an available validation
cohort of 3,962 RA cases and 3,531 controls from the
UK. A P-value of 0.004 was selected as the nominal sig-
nificance threshold. The study had between 67% and
99% power to detect association with the CeD loci in
this sample at the P < 0.004 threshold assuming the
same allele frequencies and effect sizes as reported with
CeD (Table S2 in Additional file 1). Duplicate samples
showed >99% concordance. All samples and SNPs met
the quality control threshold of >90% genotyping suc-
cess. All SNP genotype frequencies conformed to
Hardy-Weinberg expectations in the controls.
One marker with previous evidence for association
with CeD was also associated with RA in the current
cohort: rs182429 mapping to the TAGAP gene OR 0.88,
95% confidence intervals (CI) 0.82 to 0.95; P-trend
0.0005) (Table 1). The TAGAP locus has previously
been identified as an RA susceptibility locus following
meta-analysis of genome-wide association studies in RA
followed by validation in independent samples, which
included samples from the current study [11]. However,
a different SNP marker (rs394581) was tested in that
study. The two SNPs were in moderate linkage disequili-
brium (LD) (r
2 = 0.32; D’ = 0.73) in the control samples
tested here but conditional logistic regression analysis
suggested that the association arises primarily from the
CeD SNP, rs182429 (P-value for rs394581 after condi-
tioning on rs182429 = 0.90).
Of the T1D SNPs tested, only rs229541, mapping to
C1QTNF6, showed nominal evidence for association but
this did not retain statistical significance at the threshold
selected (OR 1.08, 95% CI 1.0 to 1.15, P = 0.04) (Table 2).
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SNP CHR position Gene MAF cases MAF controls P_HWE case_11 case_12 case_22 control_11 control_12 control_22 P_trend Allelic OR (95% CI)
rs2816316 1 190803436 RGS1 0.17 0.18 0.31 119
(3.3)
1027
(28.2)
2501
(68.6)
99
(3.4)
835
(28.5)
1993
(68.1)
0.65 0.98
(0.89 to 1.07)
rs917997 2 102437000 IL18RAP 0.23 0.22 0.87 208
(5.7)
1,285
(35.2)
2,154
(59.1)
147
(5.0)
1,013
(34.6)
1,771
(60.4)
0.17 1.06
(0.98 to 1.15)
rs6441961 3 46327388 CCR3 0.31 0.31 0.76 350
(9.6)
1,582
(43.3)
1,720
(47.1)
280
(9.6)
1,239
(42.3)
1,409
(48.1)
0.52 1.03
(0.95 to 1.1)
rs333 3 46389951 CCR5 0.1 0.11 0.38 23
(0.7)
689
(19.6)
2,802
(79.7)
35
(1.1)
642
(20.6)
2,444
(78.3)
0.08 0.91
(0.81 to 1.01)
rs17810546 3 161147744 IL12A 0.12 0.12 0.66 52
(1.4)
736
(20.2)
2,862
(78.4)
45
(1.5)
616
(21.1)
2,264
(77.4)
0.32 0.95
(0.85 to 1.05)
rs1464510 3 189595248 LPP 0.45 0.44 0.72 697
(19.9)
1,730
(49.4)
1,077
(30.7)
617
(19.9)
1,524
(49.1)
966
(31.1)
0.82 1.01
(0.94 to 1.08)
rs182429 6 159389562 TAGAP 0.42 0.45 0.82 600
(17.0)
1,770
(50.2)
1,159
(32.8)
590
(20.5)
1,421
(49.3)
870
(30.2)
0.0005 0.88
(0.82 to 0.95)
rs653178# 12 110492139 SH2B3 0.49 0.51 0.68 914
(25.1)
1,744
(47.9)
985
(27.0)
771
(26.4)
1,449
(49.6)
703
(24.1)
0.02 0.92
(0.86 to 0.98)
#r
2 = 1 with rs3184504; 11 = homozygote for minor allele, 12 = heterozygote, 22 = homozygote for major allele; CHR, chromosome; MAF, minor allele frequency; P_HWE, P-value for Hardy Weinberg equilibrium test.
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Table 2 Association testing of six T1D associated SNPs not previously investigated for association with RA in the current cohort
SNP CHR position Gene MAF cases MAF controls P_HWE case_11 case_12 case_22 control_11 control_12 control_22 P_trend Allelic OR
(95% CI)
rs11755527 6 91014952 BACH2 0.46 0.46 0.91 729
(20.8)
1,790
(51.0)
990
(28.2)
669
(21.5)
1,551
(49.9)
891
(28.6)
0.86 0.99
(0.93 to 1.06)
rs689 11 2138800 INS 0.28 0.28 0.54 287
(8.2)
1,411
(40.1)
1,818
(51.7)
254
(8.2)
1,246
(40.0)
1,612
(51.8)
0.95 1.00
(0.93 to 1.08)
rs12708716 16 11087374 CLEC16A 0.36 0.36 0.63 507
(12.9)
1,791
(45.4)
1,643
(41.7)
453
(12.9)
1,596
(45.5)
1,455
(41.5)
0.88 1.00
(0.93 to 1.06)
rs3825932 15 77022501 CTSH 0.32 0.32 0.77 368
(10.5)
1,506
(43.1)
1,619
(46.3)
323
(10.4)
1,366
(44.1)
1,407
(45.4)
0.62 0.98
(0.91 to 1.06)
rs3788013 21 42714397 UBASH3A 0.45 0.43 0.86 705
(20.1)
1,752
(49.9)
1,052
(30.0)
590
(19.0)
1,522
(49.0)
996
(32.0)
0.07 1.07
(1.00 to 1.14)
rs229541 22 35921264 C1QTNF6 0.45 0.43 0.49 726
(20.6)
1,693
(48.1)
1,100
(31.3)
564
(18.1)
1,548
(49.6)
1,007
(32.3)
0.04 1.08
(1.00 to 1.15)
11 = homozygote for minor allele, 12 = heterozygote, 22 = homozygote for major allele; CHR, chromosome; MAF, minor allele frequency; P_HWE, P-value for Hardy Weinberg equilibrium test.Interestingly, this gene lies close to the IL2RB gene,
which has previously been associated with RA suscept-
ibility [6]. The apparent lack of association detected
with T1D susceptibility loci in our sample may result
from limited power to detect the effect sizes reported
with the larger T1D samples: for three of the six loci,
there was <40% power to detect association at the P <
0.004 threshold (Additional file 1 Table S2). However,
association with the INS, CLEC16A and CTSH loci can
be excluded with more confidence.
The three autoimmune diseases examined in the cur-
rent study are characterised by the presence of autoanti-
bodies and, interestingly, the association of the TAGAP
variant is stronger in the subgroup of RA patients with
anti-cyclic citrullinated peptide (anti-CCP) antibodies
(P-trend = 0.0001, allelic OR 0.83 95% CI 0.75 to 0.91),
suggesting a possible role in control of B cell function.
Discussion
By investigating the genetic overlap of CeD genes with
R A ,w eh a v ei d e n t i f i e dt h eTAGAP locus as being asso-
ciated with RA. Our findings confirm and refine the
results of a previous study in RA that also showed asso-
ciation to the TAGAP region but with a different var-
iant; our results show that the same SNP that is
associated with CeD and T1D also shows stronger evi-
dence for association with RA [11]. Data from the cur-
rent study extend that of previous work identifying that
CTLA-4,t h eIL2_21 region, 6q23 (TNFAIP3), SH2B3,
PRKCQ, MMEL1 and now TAGAP are susceptibility loci
that are common to the three autoimmune diseases
examined in the current study: T1D, CeD and RA [2,5].
The current study is limited by the fact that, because
the identification of novel susceptibility markers is pro-
gressing rapidly, a number of additional CeD and T1D
susceptibility loci have been identified more recently,
which have not been tested as yet for association with RA
[12-14]. Hence, this is not a comprehensive examination
of the overlap among all T1D, CeD and RA loci. How-
ever, of the loci tested so far, there appears to be greater
overlap between T1D/CeD and T1D/RA than between
CeD and RA. This may reflect the fact that larger sample
sizes were used to investigate T1D (> 8,000 T1D cases vs
>9,000 controls) than CeD (2,500 cases vs >9,000 con-
trols), thereby reducing the possibility of false negative
results in the T1D series. The lack of association of some
of the CeD loci with RA could reflect lack of power, par-
ticularly if winner’sc u r s ehas resulted in an overestima-
tion of the effect sizes originally reported in the CeD
studies. However, effect sizes observed when data from
four GWAS of CeD were combined by meta-analysis
were similar to those reported in the study by Smyth
et al., which was used to select the CeD variants for test-
ing in the current study [2,13]. That suggests that
winner’s curse and over-estimation of effects sizes in CeD
cannot explain the lack of association observed with RA.
The TAGAP minor allele confers protection against RA,
similar to previous reports of T1D but contrasting with
CeD in which the minor allele is associated with risk. Our
results confirm and extend the evidence that there are
common autoimmune susceptibility genes but suggest that
the overlap of RA is stronger with TID than CeD.
Relatively little is known about the TAGAP gene,
which encodes a protein (T-cell activation RhoGTPase
activating protein) transiently expressed in activated
T cells, suggesting that it may have a role in immune
regulation [2].
The TAGAP gene has previously been associated with
RA following meta-analysis of US and European RA
cohorts, although a different variant mapping to the
same locus was genotyped [11]. Nonetheless, the same
UK samples tested as part of the current study were
also included in the validation phase of the meta-analy-
sis and so data for both variants was available. The
results of conditional logistic regression analysis suggest
that the primary effect is with the CeD variant tested in
the current study and that the association reported pre-
viously with rs394581, may have arisen due to LD, at
least in the UK samples.
It is interesting to note that the SNP tested at the CCR5
locus which is associated with both T1D and CeD, also
showed a trend towards association with RA. A previous
meta-analysis of studies in RA investigating this deletion
variant within the gene is suggestive of association with
RA [15]. A combined meta-analysis, including data from
the previous meta-analysis, two subsequent reports [16]
and the current data, reveals statistically significant evi-
dence for association (P =1 . 4×1 0
-5) but because of het-
erogeneity between the studies, these results should be
interpreted with caution (Figure 1).
Exploring the genetic overlap between related diseases
may reveal key common pathways that could suggest
therapeutic targets applicable to more than one disease.
However, the susceptibility loci unique to a particular
disease are also of interest; differences may reflect genu-
ine specificity between the diseases and may influence
what determines the particular autoimmune phenotype.
Of the confirmed non-HLA RA susceptibility loci
(reviewed in [17]), only the CD40 and TRAF1/C5 variants
have not been reported to be associated with either CeD
or T1D although CD40 is associated with autoimmune
thyroiditis [18]. Even the TRAF1/C5 association is not
unique to RA as there have been reports of association
with juvenile idiopathic arthritis and systemic lupus
erythematosus [19,20]. Despite the inherent bias arising
from the fact that loci associated with one autoimmune
disease are often subsequently targeted for investigation
i no t h e ra u t o i m m u n ed i s e a s e s ,t h ed e g r e eo fg e n e t i c
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that specificity of the autoimmune phenotype is deter-
mined by the particular HLA associations of each disease
that could either directly or indirectly influence the
response to environmental agents. This hypothesis would
require further investigation in well-powered cohorts
with both genetic and reliable environmental data.
In summary, we report association of RA with the
TAGAP gene, identified through targeting loci pre-
viously associated with CeD. The findings identify that
the same SNP associated with T1D and CeD shows
stronger association with RA than a previously reported
variant and extend the evidence for overlap between
autoimmunity genes.
Conclusions
The TAGAP gene, previously associated with both T1D
and CeD, is also associated with RA susceptibility. This
confirms the finding of a previous study showing asso-
ciation of the TAGAP l o c u sw i t hR Ab u ts u g g e s t st h a t
the variant associated with autoimmune diseases is more
strongly associated than that reported previously.
Additional material
Additional file 1: Overlapping genetic susceptibility variants between
three autoimmune disorders - supplementary information. The file
contains tables showing the clinical characteristics of the RA patient
samples tested as well as the power of the study for each SNP tested.
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